Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 1;50(7):e391-e400.
doi: 10.1097/RLU.0000000000005918. Epub 2025 Apr 29.

Assessment of Hypoxia Before Radioembolization Treatment With 18 F-FMISO PET : ARTE-MISO Trial

Cigdem Soydal  1 , Burak Demir  2 , Emre Can Celebioglu  3 , Ecenur Dursun  1 , Gizem Inal  1 , Nuriye Ozlem Kucuk  1 , Mehmet Sadik Bilgic  3
Affiliations
Clinical Trial

Assessment of Hypoxia Before Radioembolization Treatment With 18 F-FMISO PET : ARTE-MISO Trial

Cigdem Soydal et al. Clin Nucl Med. .

Abstract

Background: Transarterial radioembolization (TARE) is a therapeutic option for patients with liver tumors. However, factors responsible for treatment resistance in TARE remain largely unknown. In this study, we aimed to investigate the role of hypoxia in the treatment response of liver tumors using 18 F-FMISO PET imaging before TARE.

Patients and methods: This single-center prospective study included 25 patients with primary or metastatic liver tumors imaged with 18 F-FMISO PET/CT before TARE and treated with 90 Y resin microspheres. Posttreatment response was assessed with 18 F-FDG PET imaging. Hypoxia status was evaluated by calculating the tumor-to-muscle (T/M) and tumor-to-blood pool (T/BP) ratios. Absorbed dose metrics were derived from 90 Y PET/MRI imaging post-procedure. Lesions were categorized by response as complete responders (CR), partial responders (PR), stable disease (SD), and progressive disease (PD). Statistical analyses included ROC curve analysis, χ2 tests, and regression models to determine predictors of treatment response.

Results: Among 25 patients (mean age: 60.4 ± 12 y, 56% males), 54 18 F-FDG-avid lesions were evaluated. The median absorbed dose (Dmean) was 114.8 Gy for CR, 98.9 Gy for PR, 56.7 Gy for SD, and 78.3 Gy for PD. Significant differences in Dmean ( P = 0.013) and T/BP ratios ( P = 0.011) were observed between responder and nonresponder groups. High Dmean lesions (>89 Gy) had a response rate of 86%, compared with 56% in low Dmean lesions. Hypoxic lesions (T/BP >1.29) showed a 57% response rate, while non-hypoxic lesions (T/BP <1.29) showed a 91% response rate. In combined analyses, while non-hypoxic/high Dmean lesions had the highest response rates (93%), hypoxic/low-dose had the lowest response rate (39%).

Conclusions: In this study, we have observed that both mean absorbed radiation dose and hypoxia status are significant predictors of response to treatment after radioembolization of liver tumors. While larger studies are needed to confirm these findings, this pilot study may pave the way for further personalized treatments to achieve better results for radioembolization.

Keywords: PET; hypoxia; molecular imaging; radioembolization.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Wiley. 2021;71:209–249.
    1. Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682–1699.
    1. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–1681.
    1. Alsultan AA, van Roekel C, Barentsz MW, et al. Dose-Response and Dose-Toxicity Relationships for Glass (90)Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. J Nucl Med. 2021;62:1616–1623.
    1. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29.

Publication types